Genetic Testing Leads Me to a PARP Inhibitor Trial
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial when the cancer returned.
Harvey Parker
This author has written 2 articles